NCT01986361View on ClinicalTrials.gov

Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method

PHASE3CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Acute PharyngitisSore Throat
Interventions
DRUG

flurbiprofen

A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.

DRUG

placebo

A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.

Trial Locations (1)

06269-4011

University of Connecticut - Student Health Services, Storrs

All Listed Sponsors
lead

Reckitt Benckiser LLC

INDUSTRY

NCT01986361 - Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method | Biotech Hunter | Biotech Hunter